血清HBV DNA与肝动脉化疗栓塞术后肝癌复发的相关性研究

doi:10.3969/j.issn.1672-5069.2010.06.007

Abstract

Abstract: Objective To identify the relationship between hepatitis B viral（HBV）DNA levels and hepatocellular carcinoma（HCC）recurrence in patients undergoing transcatherter arterial chemoembolization（TACE）. Methods 193 patients with HBV-related HCC were treated with TACE. Then，the risk factors for posttreatment recurrence of HCC were analyzed. Results 169 cases（87.6%）developed tumor recurrence two years after TACE；Multivariate analysis showed that Child-Pugh class B or C，multiple tumors，larger tumors and high HBV viral DNA levels were the independent risk factors for recurrence of HCC.Conclusion High serum HBV DNA level before TACE is one of the most important risk factors for posttreatment recurrence.

Key words: Hepatocellular carcinoma, Hepatitis B virus DNA, Transcatherter arterial chemoembolization

JI Wei，GUO Yingjun，YANG Yan，et al.. The effects of hepatitis B viral DNA load on recurrence of hepatocellular carcinoma after transcatherter arterial chemoembolization[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(6): 418-419.

References

[1] LIU L，REN ZG，SHEN Y，et al. Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: relevance of epithelial-mesenchymal transition[J]. Cancer Sci，2010，101（1）:120-128.
[2] MARELLI L，SHUSANG V，BUSCOMBE JR，et al. Transarterial injection of（131）I-lipiodol，compared with chemoembolization，in the treatment of unresectable hepatocellular cancer[J]. J Nucl Med，2009，50（6）:871-877.
[3] PLEGUEZUELO M，MARELLI L，MISSERI M，et al. TACE versus TAE as therapy for hepatocellular carcinoma[J]. Expert Rev Anticancer Ther，2008，8（10）:1623-1641.
[4] OSUGA K，HORI S，HIRAISHI K. Bland embolization of hepatocellular carcinoma using superabsorbent polymermicrospheres[J]. Cardiovasc Intervent Radiol，2008，31（6）:1108-1116.
[5] MIRAGLIA R，PIETROSI G，MARUZZELLI L，et al. Efficacy of transcatheter embolization/chemoembolization（TAE/TACE）for the treatment of single hepatocellular carcinoma[J]. World J Gastroenterol，2007，13（21）:2952-2955.
[6] MARELLI L，STIGLIANO R，TRIANTOS C，et al. Transarterial therapy for hepatocellular carcinoma:which technique is more effective A systematic review of cohort and randomized studies[J]. Cardiovasc Intervent Radiol，2007，30（1）:6-25.
[7] OKITA K. Clinical aspects of hepatocellular carcinoma in Japan[J]. Intern Med，2006，45（5）:229-233.
[8] CILLO U，VITALE A，GRIGOLETTO F，et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system[J]. J Hepatol，2006，44（4）：723-732.
[9] 中国抗癌协会肝癌专业委员会. 原发性肝癌诊断标准[J]. 中华肝脏病杂志，2000，8（3）：135.
[10] CAbIBBO G，CRAXI A. Epidemiology，risk factors and surveillance of hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci，2010，14（4）:352-355.

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.

The effects of hepatitis B viral DNA load on recurrence of hepatocellular carcinoma after transcatherter arterial chemoembolization

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments